This cybersecurity firm specializing in cloud solutions reported a notable insider sale amid a steady reduction in direct holdings.

Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for ...